52 terminated. 52 Phase 2, 28 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 52 | Terminated 52 |
| Phase 1 | 28 | Terminated 28 |
Follow Solid Tumor: new trials by email Literature Review of Solid Tumor trials Research Report on Solid Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors IBI3004 - Solid Tumor | Phase 1 / Phase 2 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 5 | 2024-08-19 | 2025-12-30 |
| Study of 23ME-01473 in Patients With Advanced Solid Malignancies 23ME-01473 - Solid Tumor | Phase 1 / Phase 2 | Terminated | 23andMe, Inc. | 5 | 2024-03-07 | 2024-12-04 |
| A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation REC-4881 - AXIN1 Gene Mutation, APC Gene Mutation | Phase 2 | Terminated | Recursion Pharmaceuticals Inc. | 18 | 2024-01-15 | 2026-02-23 |
| A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically OMX-0407 - Solid Tumor | Phase 1 / Phase 2 | Terminated | iOmx Therapeutics AG | 68 | 2023-03-30 | 2026-07-24 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy Allocetra-OTS, Nivolumab, Tislelizumab - Solid Tumor, Peritoneal Metastases | Phase 1 / Phase 2 | Terminated | Enlivex Therapeutics RDO Ltd. | 14 | 2022-11-15 | 2024-04-17 |
| Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors GT201 - Solid Tumor | Phase 1 / Phase 2 | Terminated | Grit Biotechnology | 6 | 2022-09-14 | 2026-04-27 |
| A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene OTX-2002, Tyrosine kinase inhibitor One, Tyrosine kinase inhibitor Two - Hepatocellular Carcinoma, Solid Tumor | Phase 1 / Phase 2 | Terminated | Omega Therapeutics | 24 | 2022-08-19 | 2025-02-03 |
| Safety and Preliminary Efficacy Trial of BNT142 in Patients With CLDN6-positive Solid Tumors BNT142 - Solid Tumor | Phase 1 / Phase 2 | Terminated | BioNTech SE | 73 | 2022-03-22 | 2026-04-08 |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors Niraparib - Solid Tumor, Breast Tumor | Phase 2 | Terminated | Tempus AI | 22 | 2022-03-15 | 2025-10-29 |
| Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors BNT141, Nab-paclitaxel, Gemcitabine - Solid Tumor, Gastric Cancer | Phase 1 / Phase 2 | Terminated | BioNTech SE | 13 | 2022-01-18 | 2024-10-02 |
| Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation Tazemetostat - Solid Tumor, ARID1A Gene Mutation | Phase 2 | Terminated | Prisma Health-Upstate | 20 | 2022-01-06 | 2026-03-17 |
| Study of Magrolimab in Patients With Solid Tumors Magrolimab, Docetaxel - Solid Tumor | Phase 2 | Terminated | Gilead Sciences | 106 | 2021-10-01 | 2025-05-08 |
| A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors PRS-344/S095012 - Solid Tumor | Phase 1 / Phase 2 | Terminated | Servier Bio-Innovation LLC | 46 | 2021-09-08 | 2026-06-16 |
| LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors Lerapolturev, 5% DDM - Solid Tumor, Bladder Cancer | Phase 1 / Phase 2 | Terminated | Istari Oncology, Inc. | 4 | 2021-08-01 | 2024-10-24 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion AB-106 - Solid Tumor | Phase 2 | Terminated | Nuvation Bio Inc. | 14 | 2021-06-01 | 2026-01-21 |
| Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma ADG106 injection, PD-1 antibody injection - Solid Tumor, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Adagene (Suzhou) Limited | 25 | 2021-03-11 | 2023-04-24 |
| Pembrolizumab And Lenvatinib In Leptomeningeal Metastases Pembrolizumab, Lenvatinib - Solid Tumor, Solid Tumor, Adult | Phase 2 | Terminated | Massachusetts General Hospital | 10 | 2021-03-08 | 2025-07-25 |
| The Efficacy and Safety of CKD516 Combined With Durvalumab in Patient Refractory Solid Tumors CKD-516 plus Durvalumab - Colorectal Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Tae Won Kim | 25 | 2021-02-24 | 2023-04-21 |
Showing 20 of 52. Sign in to see all of them.
Neoplasms (9) · Neoplasm Metastasis (7) · Colorectal Neoplasms (6) · Melanoma (6) · Breast Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Endometrial Neoplasms (4) · Esophageal Neoplasms (4) · Hematologic Neoplasms (4) · Lymphoma (4) · Pancreatic Neoplasms (4) · Stomach Neoplasms (4) · Urinary Bladder Neoplasms (4) · Brain Neoplasms (3) · Carcinoma, Renal Cell (3)
Neoplasms by Site (27) · Neoplasms (25) · Neoplasms by Histologic Type (20) · Neoplasms, Glandular and Epithelial (12) · Skin Diseases (12) · Skin and Connective Tissue Diseases (12) · Carcinoma (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Hemic and Lymphatic Diseases (10) · Adenocarcinoma (9)
atezolizumab (3) · pembrolizumab (3) · rucaparib (3) · Docetaxel (2) · Gemcitabine (2) · Ipilimumab (2) · Nivolumab (2) · 130-nm albumin-bound paclitaxel (1) · Bortezomib (1) · CB-839 (1) · CH5183284 (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · DDMS (1)
BioNTech SE (4) · CytomX Therapeutics (2) · Dana-Farber Cancer Institute (2) · M.D. Anderson Cancer Center (2) · Pfizer (2) · pharmaand GmbH (2) · 23andMe, Inc. (1) · 4D pharma plc (1) · AHS Cancer Control Alberta (1) · Adagene (Suzhou) Limited (1) · Albert Einstein College of Medicine (1) · Aminex Therapeutics, Inc. (1) · Bristol-Myers Squibb (1) · Calithera Biosciences, Inc (1) · Columbia University (1)
United States (41) · Spain (12) · Australia (7) · France (6) · United Kingdom (6) · South Korea (5) · Canada (4) · China (4) · Netherlands (4) · Belgium (3) · Denmark (3) · Poland (3) · Singapore (3) · Brazil (2) · Finland (2)
Apostolia Tsimberidou, MD, PHD (1) · Chaoyuan Kuang, MD, PhD (1) · Ely Benaim, MD (1) · Jaba Kokhreidze, MD (1) · James Yao, MD (1) · Jeffrey A. Sosman, MD (1) · Jennifer Low, M.D,Ph.D (1) · Ki Chung, MD (1) · Kim Reiss-Binder, MD (1) · Lawrence Lu, MD (1)
PMID 25086465, PMID 29188469, PMID 31753029, PMID 31780255, PMID 31953313, PMID 34301808, PMID 34301809, PMID 34951522, PMID 35176457, PMID 37038005, PMID 37173365, PMID 37592303, PMID 37860278, PMID 38776391, PMID 40632975, PMID 42390142, PMID 42826365
2018 (3), 2019 (3), 2014 (1), 2015 (1), 2023 (1), P30CA012197 (1)